Business Wire

STALICLA

18.10.2019 00:03:06 CEST | Business Wire | Press release

Share
STALICLA Appoints Stéphane Baudouin as Chief of Science

STALICLA is delighted to announce the appointment of Stéphane Baudouin as Chief of Science effective from October 10, 2019. Stéphane takes over as Chief of Science from Luigi Boccuto, who will continue as Assistant Research Scientist at Greenwood Genetic Center (SC, USA).
STALICLA will pursue its collaboration with the Greenwood Genetic Center, which is a leading translational research center in genetics and neurodevelopmental disorders, including ASD.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005803/en/

Dr. Baudouin is a neurobiologist with extensive research experience in the pathophysiology of Autism Spectrum Disorder. His previous work focused on the identification of molecular pathways and neuronal networks involved in the development of social skills and their breakdown in pathological conditions. Before joining STALICLA, Stéphane was a Senior Lecturer and Team Leader at Cardiff University working on research projects funded by the Wellcome Trust and the Welsh Government. Stéphane has extensive track record of collaboration within the ASD basic and translational research community notably on ASD pharmacology related research. His work has been published in numerous high impact peer-reviewed scientific journals.

Commenting on the appointment, Stéphane said:
“My decision to join STALICLA was motivated by the need to bring tangible advancement to how ASD is treated and real change to the lives of people living with these disorders. STALICLA’s approach to bringing personalized treatments to the neurodevelopmental disorder field is unique and potentially transformational. I’m excited to be part of this team and apply my experience to achieve this goal.”

Stéphane was an active member of STALICLA’s Scientific Advisory Board for over two years prior to taking up the new position. As Chief of Science, he will have overall responsibility to shape STALICLA’s pre-clinical development strategy. He will also be in charge of identifying and managing novel partnerships to support STALICLA’s regulatory needs.

“Stéphane’s extensive experience in the cellular and molecular underpinnings of Autism Spectrum Disorder will be invaluable to our research which focuses on the translation of biological and clinical data to develop precision therapeutics for patients with ASD. He is an incredibly talented addition to our team of experts and I wish him every success in his new role as Chief of Science.”
said Lynn Durham, STALICLA’s CEO & Founder

About STALICLA

STALICLA is a near clinical Company developing a first in class precision medicine platform to accelerate drug development for patients with Neurodevelopmental Disorders (NDD). First focus of development has been Autism Spectrum Disorder (ASD). Today, patients diagnosed with ASD account for 1-1.5% of the world population. The condition remains a high unmet medical need.
In its Geneva and Barcelona units, STALICLA has assembled a world class team of experienced drug developers and computational biologists. The company is recognized as a disruptive player, using its DEPIv3 innovative systems biology AI platform. DEPIv3 integrates domain specific large-scale genetic, molecular, pharmacological and clinical data to define patient subgroups and to identify personalized treatments.
It is the first time that such technologies have been utilized within the field of neurodevelopment with the potential to change the direction of the specialty.
In just over 2 years, the STALICLA platform has already proven successful in expediting and de-risking drug development for a first subgroup of patients with Autism and identifying two additional subgroups.
STALICLA’s first therapeutic package - STP1 - addresses this first distinct subgroup of ASD patients estimated to 1.5 - 2M people in the EU and North America. Clinical entry for STP1 is planned in Q1 2020.
To support its platform and pipeline development, STALICLA has developed a network of top tier research and clinical partners in the US.
This has enabled STALICLA to gather one of the largest Autism patients Electronic Health Records database to date.

STALICLA is currently scaling up DEPIv3 to advance new pipelines for additional groups of patients with NDDs.

For more information : http://www.stalicla.com/news/stalicla-pre-ind-meeting-with-fda-on-stp1/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 15:45:00 CET | Press release

We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live

Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 15:39:00 CET | Press release

Two new AI capabilities, available now. Visual Intelligence turns camera footage into production data. Factbird MCP gives AI assistants direct access to production data in Factbird. Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real c

Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 15:17:00 CET | Press release

Collaboration brings together Argenta's Molecule to Market capabilities and Loyal’s lifespan extension therapeutics with early development of LOY-003 Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candida

NIKE, Inc. Unveils the Next Generation of Innovation Across Performance Sports and Sportswear16.11.2026 15:08:00 CET | Press release

From the next evolution of Nike Air to new Nike Mind and Nike Free footwear, Nike is solving distinct athlete needs — and creating platforms that can bring those breakthroughs to more athletes.New innovations and platforms span running, training, basketball, football and outdoor sports, reflecting Nike's focus on delivering best-in-class performance to athletes across disciplines.Nike is bringing performance innovation into everyday style, reinventing the classics athletes love while introducing new silhouettes, including Project Ride and Nike Morpho X.Much of what Nike is showing arrives over the coming year, with some innovations following later. Watch for more details in the months to come. NIKE, Inc. (NYSE: NKE) is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. This press release features multimedia. View the full release here: https://www.businesswire.com

2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 13:00:00 CET | Press release

The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “F

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye